Analysts Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Price Target at $57.10

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has received a consensus recommendation of “Buy” from the eleven analysts that are covering the stock, MarketBeat reports. Ten equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $57.10.

Several research firms have commented on MIRM. Leerink Partners lifted their price target on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. HC Wainwright reissued a “buy” rating and issued a $66.00 price target on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Citigroup raised their price objective on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, Robert W. Baird boosted their target price on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th.

Insider Activity

In related news, COO Peter Radovich sold 2,627 shares of Mirum Pharmaceuticals stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $48.22, for a total value of $126,673.94. Following the sale, the chief operating officer now owns 26,961 shares in the company, valued at $1,300,059.42. The trade was a 8.88 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Christopher Peetz sold 7,489 shares of the company’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $320,678.98. Following the completion of the transaction, the chief executive officer now owns 119,359 shares of the company’s stock, valued at $5,110,952.38. This trade represents a 5.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 43,415 shares of company stock valued at $2,015,670. Company insiders own 22.87% of the company’s stock.

Institutional Trading of Mirum Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Jones Financial Companies Lllp grew its holdings in shares of Mirum Pharmaceuticals by 100.0% during the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company’s stock worth $30,000 after acquiring an additional 357 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Mirum Pharmaceuticals by 22.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after purchasing an additional 318 shares in the last quarter. R Squared Ltd purchased a new stake in Mirum Pharmaceuticals in the fourth quarter worth $69,000. AlphaQuest LLC raised its holdings in Mirum Pharmaceuticals by 969.6% in the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company’s stock worth $76,000 after purchasing an additional 1,658 shares in the last quarter. Finally, Avanza Fonder AB purchased a new position in Mirum Pharmaceuticals during the fourth quarter valued at $189,000.

Mirum Pharmaceuticals Stock Performance

NASDAQ MIRM opened at $51.06 on Monday. Mirum Pharmaceuticals has a 52-week low of $23.14 and a 52-week high of $53.49. The company has a fifty day moving average of $44.80 and a 200-day moving average of $42.33. The company has a market capitalization of $2.45 billion, a P/E ratio of -25.28 and a beta of 0.96. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.15. The firm had revenue of $90.38 million during the quarter, compared to analyst estimates of $81.99 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company’s revenue was up 89.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.57) earnings per share. As a group, equities research analysts predict that Mirum Pharmaceuticals will post -1.44 EPS for the current fiscal year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.